3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasms
2
Breast Neoplasms
2
Renal Insufficiency
1
Prostatic Neoplasms
1
Paraproteinemias
1
Neoplasms, Plasma Cell
1
Neoplasms by Histologic Type
1
Multiple Myeloma
1
Mastocytosis, Systemic
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Hairy Cell
1
Leukemia
1
Kidney Neoplasms
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Hematologic Diseases
1
Carcinoma, Renal Cell
1
Carcinoma, Medullary
1
Burkitt Lymphoma
1
Breast Carcinoma In Situ
1
Brain Neoplasms
1
Blood Protein Disorders
1
Blastic Plasmacytoid Dendritic Cell Neoplasm
1
Advanced Cancer
1
Interventions
Docetaxel
277
Prednisone
237
enzalutamide
177
Leuprolide
172
Radiotherapy
164
Abiraterone Acetate
154
Magnetic Resonance Spectroscopy
147
bicalutamide
137
Goserelin
134
Androgen Antagonists
111
Radiosurgery
101
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
100
apalutamide
79
abiraterone
77
gallium 68 PSMA-11
74
Specimen Handling
67
darolutamide
58
Gonadotropin-Releasing Hormone
58
Radiation
56
Triptorelin Pamoate
53
cabazitaxel
50
Zoledronic Acid
49
pembrolizumab
48
Radiotherapy, Intensity-Modulated
47
Flutamide
47
Brachytherapy
47
luprolide acetate gel depot
46
Standard of Care
45
Carboplatin
44
Estramustine
43
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Prostatic Neoplasms
×
Ranitidine
×
Clear all
NCT02441894
2017-01-24
PEGAZUS
Sanofi
Phase 4
Completed
21 enrolled